Svelte Medical Systems has treated its first patient at Auckland City Hospital in Auckland, New Zealand, in the DIRECT study.

DIRECT is a first-in-man, multicentre clinical study that will involve 30 patients to evaluate the feasibility of Svelte’s All-In-One system.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The CE marked All-In-One system is a low profile flexible drug-eluting system that integrates a thin-strut cobalt chromium stent with a fully bio-erodable drug carrier and the drug Sirolimus (rapamycin).

Svelte’s drug delivery system incorporates a proprietary balloon control band technology providing uniform and controlled balloon growth, facilitating physicians to ‘direct-stent’ coronary artery lesions, while reducing procedure time and cost.

The company plans to market its drug-eluting stent on a conventional rapid-exchange delivery platform, and to expand it into larger studies in 2012.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact